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Background. Abacavir hypersensitivity is strongly associated with the human leukocyte antigen(HLA)–B*5701
allele; however, the cost of routine high-resolution HLA typing before initiation of therapy remains prohibitive.
We propose a simple approach to reduce B*5701-associated abacavir hypersensitivity based on the screening of
human immunodeﬁciency virus (HIV) reverse transcriptase (RT) for a signature B*5701-associated cytotoxic T
lymphocyte escape mutation at RT codon 245.
Methods. The correlation between HLA-B*5701 and RT codon 245 variation was investigated in 392 HIV-
infected, antiretroviral-naive adults who were initiatinghighlyactiveantiretroviraltherapy.Therelationshipbetween
codon 245 variation and premature abacavir discontinuation was investigated in a larger cohort of treated indi-
viduals ( ). Associations between HLA-B*5701 and codon 245 variants were determined using Fisher’s n p 982
exact test or the x
2 test.
Results. A very strong association between HLA-B*5701 and RT codon 245 variation was observed. Only 1
(4.2%) of 24 subjects with B*5701 harbored virus with the clade B “wild-type” amino acid 245V, compared with
278 (75.5%) of 368 who did not have B*5701 ( ). The sensitivity and speciﬁcity of codon 245 substitutions P ! .001
for predicting HLA-B*5701 were 96% and 75%, respectively, and the positive and negative predictive values were
20% and 99.6%, respectively. This association remained robust even after antiretroviral treatmentwasadministered
(negative predictive value, 100%; ). In abacavir-treated individuals ( ), codon 245 substitutions n p 269 n p 982
were predictive of premature abacavir discontinuation ( ). P p .02
Conclusions. As HIV RT sequence is incidentally obtained as a part of routine drug-resistance testing, the
examination of sequence variation at RT codon 245 could be adopted as a simple, low-cost screening method to
identify individuals who could be safely treated with abacavir and/or who could beneﬁt from HLA characterization.
Cytotoxic T lymphocytes (CTLs) recognizing human
leukocyte antigen (HLA) class I–restrictedviralepitopes
presented on the surface of infected cells play a major
role in the immune control of HIV-1 infection [1].
However, HIV is able to evade host CTL responses
through the accumulation of speciﬁc mutations in
Received 2 November 2006; accepted 12 February 2007; electronicallypublished
18 April 2007.
a C.K.S.C. and Z.L.B. contributed equally to this article.
b Present afﬁliation: Partners AIDS Research Center, Massachusetts General
Hospital, Boston, Massachusetts (Z.L.B. and C.J.B.).
Reprints or correspondence: Dr. Richard Harrigan, 603-1081 Burrard St.,
Vancouver, BC, Canada, V6Z 1Y6 (prharrigan@cfenet.ubc.ca).
Clinical Infectious Diseases 2007;44:1503–8
  2007 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2007/4411-0018$15.00
DOI: 10.1086/517499
HLA-restricted CTL epitopes [1, 2]. This phenomenon,
known as “CTL escape,” has been documented on both
an individual basis [1–4] and a population basis [5],
and HLA class I–mediated selection pressure is now
recognized as a major force shaping in-host—as well
as populational—HIV sequence evolution [5]. Indeed,
available data indicate that selection of CTL escapemu-
tations occurs along common and reproducible mu-
tational pathways [3, 5], suggesting that viral evolution
may be largelypredictableonthebasisofanindividual’s
HLA class I proﬁle [3].
In addition to representing a major force shaping
viral sequence evolution, the HLA class I locus is also
strongly associated with immune-mediated hypersen-
sitivity reactions to speciﬁc antiretroviral agents. For
example, the HLA class I allele B*5701 is strongly
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associated with a 1100-fold increased risk of hypersensitivity
reaction to the nucleoside analogue reverse-transcriptase in-
hibitor (NRTI) abacavir [6–8], particularly in the context of
the 57.1 ancestral haplotype containing HLA-B*5701, HLA-
DR7, and HLA-DQ3 [6]. This hypersensitivity is a dramatic,
idiosyncratic reaction that occurs in 4%–8% of patients who
initiate abacavir therapy [9]. This reaction compromises treat-
ment and is an absolute contraindication for future abacavir
use, with potentially life-threatening consequences upon re-
challenge[9].Studieshavebeguntoevaluatetheutilityof“skin-
patch” testing for abacavir hypersensitivity [10, 11], andgenetic
screening for HLA-B*5701 [11–13] is likely to be useful in the
clinical setting [14]. Unfortunately, routine high-resolution
HLA typing remains relatively costly, and its accessibility varies
greatly, from approaching a standard of care in some regions
to being rarely available in others. These factors presentbarriers
to widespread implementation of this pharmacogenetic ap-
proach to prescribing abacavir [15].
On the basis of independent observations that selection of
CTL escape mutations are reproducible among individuals
sharing HLA alleles [3, 5] and that HLA-B*5701 screening is
likely to be recommended prior to initiating abacavir-contain-
ing regimens, we hypothesized that the presence of a signature
HLA-B*5701–selected CTL escape mutation in HIV reverse
transcriptase (RT) [16, 17], identiﬁed as a part of routine HIV
drug-resistance testing, may serve as an indirect marker for the
presence of HLA-B*5701 among HIV subtype B–infected in-
dividuals and, thus, as a simple and cost-effective prescreening
method to identify persons who are at risk for the abacavir
hypersensitivity reaction. Here we show that the presence of
an HLA-B*5701–associated amino acid change at HIV RT co-
don 245 [3, 16, 17], which lies within a known HLA-B*5701–
restricted epitope spanning codons 244–252[16,18],represents
a highly sensitive method of identifying possible B*5701-ex-
pressing individuals. Conversely, the presence of HLA-B*5701
is exceedingly rare in individuals harboring the “wild-type”
amino acid at RT codon 245; therefore, the presence of wild-
type 245V (where V represents the HIV subtype B consensus)
could be used to identify individuals who may be safely treated
with abacavir.
METHODS
Study Subjects
The British Columbia HIV/AIDS Drug Treatment Program.
In the province of British Columbia, Canada, antiretroviral
drugs are distributed free-of-charge to HIV-infectedindividuals
through a centralized HIV/AIDS drug treatment program, pre-
viously described in detail [19]. Antiretroviral drugs are pre-
scribed according to speciﬁc guidelines set by the British Co-
lumbia Therapeutic Guidelines Committee, which are revised
regularly and are in accordance with international guidelines.
Sociodemographic, therapeutic, and clinical data (including
CD4 cell counts and plasma viral loads determined at baseline
and approximately every 3 months thereafter) from persons
enrolled in the British Columbia drug treatment program are
stored in a centralized database.Sinceitsinception,∼7000HIV-
infected British Columbians have received treatment through
the drug treatment program.
The HAART Observational Medical Evaluation and Re-
search (HOMER) cohort. The HOMER cohort is an open,
treatment-based cohort that includes all antiretroviral-naive
adult British Columbians who have initiated HAART through
the drug treatment program since August 1996 [19]. It has
been the focus of a number of population-based studies and
has been described in detail previously [20–23]. This study
represents a nonrandom sample of HOMER subjects who ini-
tiated HAART between August 1996 and September 1999
( ) for whom a blood sample for HLA typing (765 of n p 1188
1188 patients) and a baseline (pretherapy) HIV drug-resistance
genotyping incorporating the sequence at RT codon 245 (392
of 765 patients) were available. These subjects represent indi-
viduals who attended St. Paul’s Hospital, Vancouver (British
Columbia), and whounderwentantiretroviral-resistancetesting
as requested by a physician or according to research protocols.
The baseline characteristics of the 392 subjects included in this
study were comparable to those of the remaining 796 HOMER
subjects for whom HLA and/or RT codon 245 data were not
available (table 1). There were no differences observed in me-
dian baseline CD4 cell count or plasma viral load ( ) P p .2
among included and excluded individuals; however, patients
included in the study were slightly older (median age, 38 vs.
37 years; ) and more likely to be male (88% vs. 83%; P p .03
) than those who were excluded. Ethics approval for P p .04
this study was obtained from the institutional ethics board of
Providence Health Care and University of British Columbia.
HLA-B Sequence-Based Typing and HIV RT Genotyping
Sequence-based typing for HLA-B was performed using DNA
extracted from a PBMC-enriched frozen blood sample that was
obtained from each subject. The sequence-based typing pro-
tocol, a validated “in-house” procedure based on International
Histocompatibility Working Group protocols, involves a nested
PCR ampliﬁcation of exons 2 and 3 of the HLA-B locus (prim-
ers available upon request), followed by bidirectional auto-
mated DNA sequencing using an ABI 3700 DNA sequencer
(Applied Biosystems). HLA allele interpretation was performed
by comparing sequence-based typing data against all alleles
listed in the Immunogenetics (IMGT)–HLA database (FTP site
available at http://www.ebi.ac.uk/imgt/hla/download.html) up
to August 2005, yielding intermediate-to-high–level resolution
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Table 1. Baseline (pretherapy) characteristics of the HAART ObservationalMedicalEvaluationandResearch(HOMER)cohort,stratiﬁed
by the availability of both human leukocyte antigen–B and HIV reverse transcriptase codon 245 data.
Baseline characteristic
Total HOMER cohort
(n p 1188)
Availability of HLA-B and RT codon 245 data
No RT codon 245
or HLA-B
data available
(n p 796)
RT codon 245
and HLA-B
data available
(n p 392) P
Male sex 1003 (84.4) 660 (82.9) 343 (87.5) .04
Age, median years (IQR) 37.1 (32.0–43.7) 36.7 (31.4–43.3) 37.9 (32.6–44.2) .03
HIV pVL, median log10 copies/mL (IQR) 5.08 (4.62–5.49) 5.08 (4.59–5.46) 5.11 (4.67–5.53) .19
CD4 cell count, median cells/mm
3 (IQR) 280 (130–420) 290 (130–430) 260 (120–400) .18
Baseline AIDS diagnosis 157 (13.2) 105 (13.2) 52 (13.3) 1.00
History of injection drug use 351 (29.6) 238 (29.9) 113 (28.8) .70
NOTE. Data are no. (%) of patients, unless otherwise indicated. IQR, interquartile range; pVL, plasma viral load.
for most alleles. Population-based HIV RT sequences up to
codon 400 were obtained from plasma HIV RNA as a part of
routine HIV drug-resistance testing, as previously described
[24]. The HOMER cohort consists of ∼97% HIV subtype B
infections [25].
Statistical Analyses
Association between a pretherapy RT codon 245 genotype and
HLA-B*5701. For each subject, the latest plasma sample col-
lected in the 180 days prior to initiation of HAART (the “base-
line” sample) was genotyped for antiretroviral resistance. As-
sociations between the presence of speciﬁc mutations at HIV
RT codon 245 at baseline and possession of each HLA-B allele
observed in our cohort were determined using Fisher’s exact
test.
Effect of exposure to HAART on the prevalence of substi-
tutions at RT codon 245. Fisher’s exact test was used to ex-
amine associations between HLA-B alleles and RT codon 245
variation in antiretroviral-resistance genotypes after initiation
of HAART. For each subject with an available post-HAART
genotype ( ), the subject’s latest “on-therapy” genotype n p 269
was used.
Association of RT codon 245 with early discontinuation of
abacavir treatment. We performed a larger analysis of all
HIV-infected individuals who were enrolled in the drug treat-
ment program who initiated abacavir-containingtherapyatany
time between March 1998 and July 2004 ( ) and who n p 1448
had HIV RT codon 245 data available ( ; 68%). The n p 982
association between RT codon 245 substitutions in thesubject’s
latest “on-therapy” genotype and premature discontinuationof
abacavir treatment was assessed using the x
2 test. We deﬁned
premature discontinuation as permanently stopping abacavir
therapy 3 months after initiation with a report of abacavir-
related adverse effects or hypersensitivity or permanently stop-
ping abacavir 1 month after initiation without a documented
reason.
RESULTS
Prevalence of HLA-B*5701 and substitutions at RT codon 245
at baseline. In the baseline (pretherapy) HOMER cohort se-
quences, HIV RT codon 245 exhibited 71% sequence conser-
vation. Consistent with the HIV-1 subtype B consensus se-
quence [26], the most common (wild-type) amino acid in our
cohort was 245V. The HLA-B*5701 allele was detected in 24
(6.1%) of 392 patients examined. We observed an exceedingly
strong association between HLA-B*5701 and polymorphisms
at RT codon 245: wild-type 245V was observed in 1 (4.2%) of
24 subjects with B*5701, compared with 278 (75.5%) of 368
subjects without B*5701 ( ). The sensitivity and speci- P ! .001
ﬁcity of the presence of non–wild-type aminoacidsatRTcodon
245 for predicting B*5701 were 95.8% (95% CI, 77%–100%)
and 75.5% (95% CI, 71%–80%), respectively;negativeandpos-
itive predictive values of this assay were 99.6% (95% CI, 98%–
100%) and 20.4% (95% CI, 14%–29%), respectively. For in-
dividuals with HLA-B*5701, the most common substitution at
RT codon 245 was E ( ; 45.8%), followed by M ( n p 11 n p
; 16.7%), L ( ; 8.3%), and others. Note that no unique 4 n p 2
characteristics were identiﬁed for the single subject (who was
an exception) who had both B*5701 and wild-type 245V at
baseline.
Other associations with substitutions at RT codon 245 at
baseline. The relatively low speciﬁcity (75.5%) of the rela-
tionship between RT codon 245 substitutions andHLA-B*5701
may be largely explained by 2 main factors. The ﬁrst is infection
with non-B HIV subtypes. All14 (3.6%)of392subjectsinfected
with non-B subtypes had non-V amino acids at RT codon 245
at baseline; however, none had HLA-B*5701. The most com-
mon amino acid substitutions at RT codon 245 among non-B
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subtypes in our cohort were Q ( ; 64.3%), followed by E n p 9
( ; 14.3%), and others. The second factor that explains n p 2
the relatively low speciﬁcity of this assay is possession of the
closely related HLA-B*58 allele, which also has a CTL epitope
overlapping RT codon 245 and also selects for an escapemutant
at this position [18]. Only 1 (6.7%) of 15 individuals with
HLA-B*58 had the HIV subtype B wild-type 245V sequence,
compared with 278 (73.7%) of 377 subjects without B*58
( ). Similar to the observations for HLA-B*5701, the P ! .001
most common substitutions at RT codon 245 for individuals
with B*58 were E ( ; 33.3%), followed by L ( ; n p 5 n p 2
13.3%), T ( ; 13.3%), and others. No other HLA-B allele n p 2
observed in our cohort was signiﬁcantly associated with vari-
ation at RT codon 245. For individuals with other HLA-B al-
leles, the most common amino acid sequence was 245V
( ; 78.5%), followed by substitutions E ( ; 5.1%), n p 277 n p 18
M ( ; 3.7%), K ( ; 3.4%), and others. n p 13 n p 12
Effect of exposure to antiretroviral therapy on the preva-
lence of substitutions at RT codon 245. To be a usefulmarker,
the association between RT codon 245 and B*5701 should not
be impaired by mutations selected by antiretroviral therapy.
Posttherapy (follow-up) RT sequences were available for 269
(68.6%) of the 392 individuals who were investigated. In the
posttherapy sequences, wild-type 245V was observed in 0 of
13 subjects with B*5701, compared with 195 (76.2%) of 256
subjects without B*5701 ( ), indicating that the asso- P ! .001
ciation between B*5701 and RT codon 245 variation remains
signiﬁcant, regardless of antiretroviral exposure. The sensitivity
and speciﬁcity of RT codon 245 substitutions for predicting
HLA-B*5701 after receiving antiretroviral therapy were 100%
(95% CI, 78%–100%) and 76.8% (95% CI, 71%–81%), re-
spectively; negative predictive value and positive predictive
value were 100% (95% CI, 98%–100%) and 19.7% (95% CI,
12%–30%), respectively. Consistent with pretherapy data, the
most common substitution at RT codon 245 in individualswith
HLA-B*5701 was E ( ; 50.0%). Six subjects experienced n p 9
a change from the wild-type sequence to RT codon 245 poly-
morphisms (all mixtures containing V) after initiation of ther-
apy, whereas 4 subjects changed from polymorphisms to the
wild-typesequence(3V-containingmixturesand1with245M);
none of these individuals had B*5701. Note that posttherapy
HIV genotype data were unavailable for the single individual
who had both B*5701 and 245V at baseline.
Association of RT codon 245 with early discontinuation of
abacavir. As a preliminary clinical validation, we wished to
examine whether sequence variation at RT codon 245 was as-
sociated with early discontinuation of abacavir treatment (de-
ﬁned as permanently stopping abacavir treatment 3 months
after initiation with a report of abacavir-related adverse effects
or hypersensitivity or permanently stopping abacavirtreatment
after 1 month without a documented reason) in a larger
group of treated individuals. Of the 1448 people who initiated
abacavir therapy in British Columbia between March 1998 and
July 2004 (regardless of previous antiretroviral therapy), RT
sequence data were available for 982 individuals (67.8%). A
total of 46 (16.4%) of 280 subjects with RT codon 245 sub-
stitutions prematurely discontinued abacavir, compared with
76 (10.8%) of 702 individuals with 245V ( ). Thus, even P p .02
with these relatively broad deﬁnitions, detection of substitu-
tions at RT codon 245 was indeed linked to early abacavir
discontinuation. The substitution 245E was present in 14% of
individuals who prematurely discontinued abacavir therapy,
compared with 8% of those who continued to receive therapy
( ). Other RT codon 245 substitutions associated with P p .005
trends toward early abacavir discontinuation were 245M (8%
vs. 5%) and K (7% vs. 4%).
DISCUSSION
The HLA-B*5701 allele, observed in 5%–10% of white indi-
viduals, is associated with a 1100-fold increased risk for the
serious and potentially fatal abacavir hypersensitivity reaction
[6–8]. On the basis of the severity of this reaction, genetic
testing for HLA-B*5701 as a screening method for abacavir use
has been simulated and found to be potentially cost-effective
[12] and clinically useful [14], and it is possible that screening
for HLA-B*5701 may be recommended for all HIV-infected
individuals who are initiating antiretroviral therapy. High-res-
olution HLA typing, however, remains a relatively time-con-
suming and costly process and, thus, the development of more-
rapid and simple B*5701 screening procedures—including
allele-speciﬁc PCR, ﬂow cytometry–based screens, or the iden-
tiﬁcation of indirect diagnostic indicators—would be advan-
tageous [15]. The availability of these HLA screening methods
varies greatly among different locations.
On the basis of previous evidence indicating that HLA class
I alleles select for reproducible patterns of escape mutations in
the HIV genome [3, 5], we hypothesized that speciﬁc HLA-
B*5701–selected sequence changes in HIV infection may serve
as an indirect marker of B*5701 expression. Here we show that
the presence of previously documented HLA-B*5701–selected
sequence changes at HIV RT codon 245 [3,16,17],representing
an escape mutation selected at the ﬁrst anchor residue of the
HLA-B*5701–speciﬁc ISW9 epitope in HIV RT, may serve as
a useful marker for HLA-B*5701 expression, whereas the pres-
ence of the clade B wild-type 245V amino acid sequence vir-
tually excludes the possibility of HLA-B*5701 expression. This
epitope is the second most frequently targeted epitope in acute
or early infection in the entire HIV genome among B*57-ex-
pressing individuals [27].
Despite only a moderate speciﬁcity, the presence of non-V
amino acid substitutions at HIV RT codon 245 (where V rep-
resents the HIV subtype B consensus or wild-type sequence)
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predicts the presence of HLA-B*5701 with extremely high sen-
sitivity (96%–100%). Similarly, although the positive predictive
value of this test was low (subjects with B*5701 account for
only 20% of all subjects with non-V substitutions at RT codon
245), the negative predictive value was 199% (meaning that
the presence of wild-type V excludes the possibility of B*5701
in 199% of cases). These results suggest the utility of examining
HIV sequence variation at RT codon 245 to identify those
individuals who are at a substantially reduced risk for the aba-
cavir hypersensitivity reaction. On the basis of the high sen-
sitivity and negative predictive value of this assay, the presence
of wild-type RT 245V (present in 170% of subtype B-infected
individuals) could be used as an indirect indicator of the ab-
sence of B*5701, thereby identifying individuals who maysafely
be treated with abacavir. This screening method would reduce
the total number of persons requiring HLA-B typing by 170%.
One limitation of this study is that we did not directly de-
termine associations between RT codon 245 sequence variation
and incidence of the abacavir hypersensitivity reaction. In the
absence of comprehensive abacavir patch test screening data,
we used an “early abacavir discontinuation” deﬁnition, which
may not accurately reﬂect the prevalence of the hypersensitivity
reaction inourcohort.Nevertheless,datasuggestthatRTcodon
245 substitutions are speciﬁcally associated with early discon-
tinuation of abacavir treatment and are not simply a marker
of therapy discontinuation in general. For example, these sub-
stitutions were not correlated with premature discontinuation
of treatment with nevirapine, an unrelated drug that has also
been associated with hypersensitivity reactions in some indi-
viduals [28]. Another limitation is that our cohort represents
a chronically HIV-infected population that was abouttoinitiate
therapy with relatively low median CD4 cell counts. Because
thetime-courseofselectionforHLA-associatedpolymorphisms
over the natural course of HIV infection remains incompletely
characterized, it is not clear whether the association between
HLA-B*5701 and RT codon 245 would be as robust earlier in
the HIV disease progression. Finally, it is important to note
that the predictive value of wild-type RT 245V to identify in-
dividuals potentially at reduced risk for the abacavir hypersen-
sitivity reaction is presently restricted to those who have HIV
subtype B infection, which represents the only subtype with
“V” as the consensus amino acid sequence at this position [26].
Additional research will be required to determine whether es-
cape from the wild-type 245Q observed in non-B clades of HIV
is also associated with HLA-B*5701. Despite this limitation,
however, this assay is still likely to be of clinical utility, given
that HIV subtype B infections predominate in North America
and Western Europe, and HLA-B*5701 is most prevalent—as
well as most strongly predictive of abacavir hypersensitivity
reactions—in white individuals [7, 8, 12].
The greatest advantage of the RT codon 245 test is that HIV
RT genotypes can be obtained through routine HIV drug-re-
sistance testing and, therefore, could be available to patients
and clinicians at no additional cost or effort. It may, therefore,
serve as a rapid and economical screening method for iden-
tifying patients who are at risk for experiencing the abacavir
hypersensitivity reaction. On the basis of the results of this
study, as well as the potential utility of using other speciﬁc HLA
class I allele–selected HIV sequence changes as indirect genetic
markers in future assays, we recommend that all commercially
available antiretroviral-resistance tests reportallaminoaciddif-
ferences, from consensus to at least RT codon 245. Finally, it
is important to note that no screening approach can replace
the need for pharmacovigilance in the decision to discontinue
abacavir treatment in patients who have clinically suspected
abacavir hypersensitivity.
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